Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
Top Cited Papers
- 1 June 2014
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 15 (7) , 700-712
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Prostate cancer: ESMO Consensus Conference Guidelines 2012Annals of Oncology, 2013
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate CancerClinical Cancer Research, 2007
- Boosting antitumor responses of T lymphocytes infiltrating human prostate cancersJournal of Experimental Medicine, 2005
- T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancerProceedings of the National Academy of Sciences, 2001